全文获取类型
收费全文 | 1225篇 |
免费 | 88篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 51篇 |
妇产科学 | 52篇 |
基础医学 | 206篇 |
口腔科学 | 18篇 |
临床医学 | 119篇 |
内科学 | 286篇 |
皮肤病学 | 85篇 |
神经病学 | 68篇 |
特种医学 | 74篇 |
外科学 | 88篇 |
综合类 | 23篇 |
一般理论 | 3篇 |
预防医学 | 68篇 |
眼科学 | 14篇 |
药学 | 112篇 |
中国医学 | 5篇 |
肿瘤学 | 66篇 |
出版年
2022年 | 12篇 |
2021年 | 12篇 |
2020年 | 14篇 |
2019年 | 14篇 |
2018年 | 34篇 |
2017年 | 10篇 |
2016年 | 23篇 |
2015年 | 25篇 |
2014年 | 33篇 |
2013年 | 31篇 |
2012年 | 46篇 |
2011年 | 43篇 |
2010年 | 46篇 |
2009年 | 42篇 |
2008年 | 49篇 |
2007年 | 69篇 |
2006年 | 73篇 |
2005年 | 46篇 |
2004年 | 52篇 |
2003年 | 48篇 |
2002年 | 34篇 |
2001年 | 26篇 |
2000年 | 21篇 |
1999年 | 23篇 |
1998年 | 33篇 |
1997年 | 25篇 |
1996年 | 35篇 |
1995年 | 14篇 |
1994年 | 26篇 |
1993年 | 13篇 |
1992年 | 20篇 |
1991年 | 15篇 |
1990年 | 28篇 |
1989年 | 17篇 |
1988年 | 28篇 |
1987年 | 23篇 |
1986年 | 18篇 |
1985年 | 23篇 |
1984年 | 14篇 |
1983年 | 12篇 |
1982年 | 14篇 |
1981年 | 9篇 |
1980年 | 10篇 |
1977年 | 7篇 |
1976年 | 8篇 |
1943年 | 7篇 |
1942年 | 7篇 |
1940年 | 8篇 |
1938年 | 7篇 |
1937年 | 6篇 |
排序方式: 共有1339条查询结果,搜索用时 15 毫秒
1.
2.
H. -J. Möller H. M. van Praag B. Aufdembrinke P. Bailey T. R. E. Barnes J. Beck H. Bentsen F. X. Eich L. Farrow W. W. Fleischhacker J. Gerlach K. Grafford B. Hentschel A. Hertkorn S. Heylen Y. Lecrubier J. P. Leonard P. McKenna W. Maier V. Pedersen A. Rappard W. Rein J. Ryan M. Sloth Nielsen R. -D. Stieglitz G. Wegener J. Wilson 《Psychopharmacology》1994,115(1-2):221-228
There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treatment of negative symptoms. Some degree of standardization would improve comparability of studies and aid the development of new compounds. Patients included in such studies should have displayed negative symptoms for at least 6 months. Depressive symptoms, positive schizophrenic symptoms and extrapyramidal signs may all influence or be confused with negative symptoms and may respond to treatment; they should be at a low level at baseline and should be measured during the study period. Studies should last at least 8 weeks. Several scales are available for measuring negative symptoms and are reviewed; a global impression score should be used additionally. 相似文献
3.
SB Miranda† O Lupi‡ E Lucas† 《Journal of the European Academy of Dermatology and Venereology》2004,18(5):622-625
Pityriasis rosea (PR) is a relatively common disease although its aetiology has not yet been identified. It occurs worldwide and there is no racial susceptibility factor. It usually affects teenagers and young adults between 10 and 35 years of age. Typical PR is much easier to diagnose than the rare atypical forms. We report a rare case of vesicular PR in a black woman who had vesicular lesions limited to her palms and soles in addition to regular typical lesions. We devised an efficient oral erythromycin treatment for this patient. 相似文献
4.
We describe how adverse drug reactions (ADRs) can play an important role in pharmaceutical research and drug development. Not only do ADRs represent the risks and drawbacks associated with drugs but they can also be related to other knowledge available in pharmaceutical and medical research. We offer a model that can be used to systematically map the pathways through which ADRs can lead to innovative research. These pathways include chemical, therapeutic or pathophysiological steps that can be taken to arrive at new knowledge based on ADRs. We used the development of angiotensin-converting enzyme inhibitors, especially captopril, as a case study. The similarity between the ADR profiles of captopril and penicillamine was a starting point for further innovation. Historical analysis shows that in several instances research in the field of angiotensin-converting enzyme inhibitors has been triggered by ADRs. The model presented here might be applicable to other areas of innovative drug research. 相似文献
5.
6.
7.
E A Stewart K V Jackson A J Friedman M S Rein J H Fox M D Hornstein 《Fertility and sterility》1992,57(6):1274-1278
STUDY OBJECTIVE: To determine the effect of baseline complex ovarian cysts on controlled ovarian hyperstimulation and in vitro fertilization (IVF) outcome. DESIGN: Retrospective analysis with stratification by stimulation regimen and the presence or absence of surgically documented endometriosis. PATIENTS: Two hundred sixty-one women undergoing IVF from May 1, 1989 to December 31, 1990. MAIN OUTCOME MEASURES: The outcome measures assessed were the maximum estradiol (E2) concentration on day of human chorionic gonadotropin (hCG) administration, number of follicles with maximum diameter greater than or equal to 15 mm, number of follicles with maximum diameter greater than or equal to 12 mm, number of days to hCG administration, number of ampules of human menopausal gonadotropin (hMG) used, number of oocytes retrieved and fertilized, number of embryos transferred, and pregnancy and cycle cancellation rates. RESULTS: There were no statistical differences between cyst and noncyst groups in any of the above parameters of IVF performance. In a single subgroup, patients with endometriosis stimulated with hMG and patients with cysts had significantly lower E2 concentrations than patients without cysts. CONCLUSION: The presence of a complex cyst on a baseline ultrasound does not appear to adversely affect IVF cycle outcomes. 相似文献
8.
9.
10.
Angus M. McLean Elizabeth Babcock-Atkinson Kathleen Rein Donald A. Ruggirello Mario A. Gonzalez Patrick K. Noonan 《Pharmaceutical research》1987,4(4):327-331
Gallopamil is a calcium-channel antagonist with reported activity in experimental animals three to five times higher than that of verapamil. An automated high-performance liquid chromatographic (HPLC) method with fluorescence detection is described for the simultaneous determination of gallopamil and its metabolite norgallopamil in plasma. Gallopamil was well resolved from norgallopamil and other metabolites, allowing simultaneous quantitation of both drugs. The detection limit for both gallopamil and norgallopamil was 0.9 ng/ml. This method has been successfully used for the determination of gallopamil and norgallopamil following the administration of 25-, 37.5-, and 50-mg oral doses of drug. 相似文献